Oncogenic and tumor suppressor function of MEIS and associated factors

Girgin B., Karadağ Alpaslan M., KOCABAŞ F.

TURKISH JOURNAL OF BIOLOGY, cilt.44, sa.6, ss.328-355, 2020 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 44 Sayı: 6
  • Basım Tarihi: 2020
  • Doi Numarası: 10.3906/biy-2006-25
  • Dergi Adı: TURKISH JOURNAL OF BIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.328-355
  • Anahtar Kelimeler: MEIS, cancer, small molecules, MEIS inhibitors, CELL LUNG-CANCER, HOMEOBOX GENE-EXPRESSION, PROTEIN-PROTEIN INTERACTIONS, EPITHELIAL OVARIAN-CANCER, SMALL-MOLECULE INHIBITORS, DNA-BINDING PARTNERS, LONG NONCODING RNAS, INTEGRATION SITE 1, PANCREATIC-CANCER, HUMAN NEUROBLASTOMA
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

MEIS proteins are historically associated with tumorigenesis, metastasis, and invasion in cancer. MEIS and associated PBX-HOX proteins may act as tumor suppressors or oncogenes in different cellular settings. Their expressions tend to be misregulated in various cancers. Bioinformatic analyses have suggested their upregulation in leukemia/lymphoma, thymoma, pancreas, glioma, and glioblastoma, and downregulation in cervical, uterine, rectum, and colon cancers. However, every cancer type includes, at least, a subtype with high MEIS expression. In addition, studies have highlighted that MEIS proteins and associated factors may function as diagnostic or therapeutic biomarkers for various diseases. Herein, MEIS proteins and associated factors in tumorigenesis are discussed with recent discoveries in addition to how they could be modulated by noncoding RNAs or newly developed small-molecule MEIS inhibitors.